Compliance research officer

It should be noted that the regulatory authority in each country still has the major say in the requirements within its territorial control even though the US FDA seems to exercise a significant influence on the regulatory requirements of other countries. Finally, it may be instructive to review the top reasons for product recalls based on a report from the FDA Center for Drug Evaluation and Research Office of Compliance ... 

CBER has three offices the Office of Compliance, the Office of Biological Product Review, and the Office of Biologies Research. The Office of Biological Product Review oversees the review of all applications to test investigational products in humans and to market new products, but staff in all three offices actually conduct the reviews. 

Other offices within ODER may become involved in the review process via consults. Eor example, the Office of Epidemiology and Biostatistics analyzes statistical data, the Office of Research Resources provides bioavailabiHty reviews, and the Office of Compliance determines from the results of inspections whether the firms meet EDA s Current Good Manufacturing Practice (cGMP) regulations. Advisory committees composed of independent experts are often asked to meet and further analyze the data. Often they also advise as to what additional data and information may be needed. After PDA s review is completed, PDA issues either a Summary Basis of Approval (SBA) for the dmg or a recommendation against approval. If approved, PDA releases the SBA and a summary of the safety and effectiveness data to the general pubHc. 

Human research issues affect all programs in US-EPA. In its Office of Research and Development, US-EPA conducts research with human subjects to provide critical information on environmental risks, exposures, and effects in humans. This is referred to as first-party research. In both its Office of Research and Development and its program offices (including the Office of Air and Radiation, the Office of Water, the Office of Solid Waste and Emergency Response, and the Office of Prevention, Pesticides and Toxic Substances), US-EPA also supports research with human subjects conducted by others. This is referred to as second-party research. In aU this work US-EPA is committed to full compliance with the common rule. The US-EPA will continue to conduct and support such research, and to consider and rely on its results in US-EPA assessments and decisions. 

Pierson, Jerry, RPh., Ph.D., Lieutenant Colonel, U.S. Army, Chief, Regulatory Affairs, Office of Regulatory Compliance and Quality, U.S. Army Medical Research and Materiel Command, April 19, 2001. 

The guidance specifies the application information that should be provided to the Center for Drug Evaluation and Research (CDER) to ensure continuing product quality and performance chacteristics of the sernisolid topical formulation for specified changes. The guidance does not comment on or otherwise affect compliance/inspection documentation defined by the Office of Compliance in CDER or the Office of Regulatory Affairs at FDA. 

In Jime 2004 with authorization of the Main Technical Department of the Russian Navy specialists of Expert-center Research and Engineering Office together with NIKIET performed a detailed radiation examination inside and outside all compartments (save for RC) of NSs 175 and 610 in compliance with a specially-developed and approved program. Dose control and spectrometric measurements allowed revealing the following maximal exposure dose rates were measured in adjacent-to-RC compartments on bulkheads from RC side (0.1-0.38 mSv/h for NS 175 and 0.83-0.9 mSv/h for NS 610). 

In the first phase of this research, a comparative analysis study was carried out on yams from the back panel of the vest that had failed in the field (manufactured in November 2002, hereinafter referred to as the officer s vest), a new, non-deployed vest of the same model and constmction as the officer s vest (manufactured in September 2003, hereinafter referred to as the new vest), and a vest from the National Law Enforcement and Corrections Technology Center (NLECTC) Compliance Test Program Archive, of the same model and constmction as the officer s vest (manufactured in March 2001 and submitted for compliance testing in May 2001, hereinafter referred to as the archive vest). 

Each of these subdivisions is typically further subdivided. For example, CBER has offices of Management, Compliance, Therapeutic Research and Review, Vaccines Research and Review, Establishment Licensing and Product Surveillance, Blood Products and Communications and Training. Each are typically led by career civil servant Office Directors, although, currently, the Office of Orphan Product Development is headed by a Rear-Admiral from the US Public Health Service. 

Thus, year after year, lyophilization is becoming a vast, diversified field for research and development, engineering, and production, still under the close eye of the administration and of the compliance officers. 

---